The focus of this present study is to investigate the effects of Resveratrol in combination with ERα agonist (E2), endocrine disrupter (BPA), and anti-estrogens (ICI and Tamoxifen) on the expression of p53 and ERα in T-47D breast cancer cells. Here, TP53 is linked to breast cancer.